SEC Filings

Form 10-K
PDS BIOTECHNOLOGY CORP filed this Form 10-K on 02/21/2019
Document Outline
Entire Document (3808.3 KB)
Subdocument 1 - 10-K - 10-K
Page 1 - UNITED STATES
Page 2 - Edge Therapeutics, Inc.
Page 3 - Cautionary Note Regarding Forward-Looking Statements
Page 4 - PART I
Page 5 - i.e.,
Page 6 - Patent Rights Associated with EG-1962
Page 7 - Government Regulation
Page 8 - Employees
Page 9 - Risks Related to the Merger
Page 10 - The combined company will need to raise additional capital by issuing securities or debt or through
Page 11 - The market price of the combined company s common stock following the merger may decline as a result
Page 12 - Risks Related to the Merger and Edge s Evaluation of Strategic Alternatives
Page 13 - The issuance of shares of Edge common stock to PDS stockholders in the merger will dilute substantia
Page 14 - Risks Related to Development and Regulatory Approval
Page 15 - Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and re
Page 16 - Failure to obtain regulatory approval in international jurisdictions would prevent Edge s product ca
Page 17 - Risks Related to Edge s Business and Industry
Page 18 - Risks Related to Edge s Intellectual Property
Page 19 - Edge may become involved in lawsuits to protect or enforce Edge s intellectual property, which could
Page 20 - Edge may be subject to claims that Edge s employees or consultants have wrongfully used or disclosed
Page 21 - Risks Related to Edge s Financial Position and Capital Needs
Page 22 - If Edge fails to continue to meet all applicable Nasdaq Global Select Market requirements and Nasdaq
Page 23 - Future sales of a substantial number of shares of Edge s common stock in the public market or other
Page 24 - Because Edge does not anticipate paying any cash dividends on Edge s capital stock in the foreseeabl
Page 25 - Edge s disclosure controls and procedures may not prevent or detect all errors or acts of fraud.
Page 26 - Edge and PDS do not anticipate that the combined company will pay any cash dividends in the foreseea
Page 27 - If the ownership of the combined company common stock is highly concentrated, it may prevent you and
Page 28 - ITEM 1B. Unresolved Staff Comments
Page 29 - PART II
Page 30 - ITEM 7. Management s Discussion and Analysis of Financial Condition and Results of Operations
Page 31 - General and Administrative Expenses
Page 32 - Income Taxes
Page 33 - Basic and Diluted Net Loss Per Share of Common Stock
Page 34 - Interest Income and Expense, net
Page 35 - Cash flows
Page 36 - Contractual Obligations and Commitments
Page 37 - JOBS Act
Page 38 - ITEM 8. Financial Statements and Supplementary Data
Page 39 - PART III
Page 40 - Robert Spiegel, M.D.
Page 41 - R. Loch Macdonald, M.D., Ph.D.
Page 42 - Corporate Governance
Page 43 - Audit Committee
Page 44 - www.edgetherapeutics.com
Page 45 - Section 16(a) Beneficial Ownership Reporting Compliance
Page 46 - Narrative to Summary Compensation Table
Page 47 - Outstanding Equity Awards at Year-End
Page 48 - Potential Payments Upon a Termination or Change in Control
Page 49 - N/A
Page 50 - Director Compensation
Page 51 - ITEM 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matt
Page 52 - ITEM 13. Certain Relationships and Related Transactions, and Director Independence
Page 53 - Retention Arrangements
Page 54 - Audit fees:
Page 55 - PART IV
Page 56 - N/A
Page 57 - N/A
Page 58 - N/A
Page 59 - SIGNATURES
Page 60 - Report of Independent Registered Public Accounting Firm
Page 61 - EDGE THERAPEUTICS, INC.
Page 62 - EDGE THERAPEUTICS, INC.
Page 63 - EDGE THERAPEUTICS, INC.
Page 64 - EDGE THERAPEUTICS, INC.
Page 65 - Edge Therapeutics, Inc.
Page 66 - Note 2 Summary of Significant Accounting Policies
Page 67 - N/A
Page 68 - New accounting standards adopted:
Page 69 - Note 4 Property and Equipment
Page 70 - N/A
Page 71 - Note 8 Income Taxes
Page 72 - Note 9 Commitments and Contingencies
Page 73 - N/A
Page 74 - N/A
Page 75 - Note 10 Debt
Subdocument 2 - EX-23.1 - EXHIBIT 23.1
Page 1 - N/A
Subdocument 3 - EX-31.1 - EXHIBIT 31.1
Page 1 - N/A
Subdocument 4 - EX-31.2 - EXHIBIT 31.2
Page 1 - N/A
Subdocument 5 - EX-32.1 - EXHIBIT 32.1
Page 1 - N/A
Subdocument 6 - EX-32.2 - EXHIBIT 32.2
Page 1 - N/A
XBRL Item - EX-101.INS - XBRL INSTANCE DOCUMENT (What's this?)
XBRL Item - EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA (What's this?)
XBRL Item - EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE (What's this?)
XBRL Item - EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE (What's this?)
XBRL Item - EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE (What's this?)
XBRL Item - EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE (What's this?)
XBRL Viewer

Printer Friendly Version Print PageE-mail this page Email PageRSS RSS FeedsE-mail Alerts Email AlertsView contacts IR Contacts